Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Published:2019-03 Issue:3 Volume:20 Page:383-393
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Bono Johann S,Concin Nicole,Hong David S,Thistlethwaite Fiona C,Machiels Jean-Pascal,Arkenau Hendrik-Tobias,Plummer Ruth,Jones Robert Hugh,Nielsen Dorte,Windfeld Kristian,Ghatta Srinivas,Slomovitz Brian M,Spicer James F,Yachnin Jeffrey,Ang Joo Ern,Mau-Sørensen Paul Morten,Forster Martin David,Collins Dearbhaile,Dean Emma,Rangwala Reshma A,Lassen Ulrik

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors;Breij;Cancer Res,2014

2. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma;Chen;Blood,2016

3. The relationship between tissue factor and cancer progression: insights from bench and bedside;van den Berg;Blood,2012

4. Tissue factor, blood coagulation, and beyond: an overview;Chu;Int J Inflam,2011

5. Role of tissue factor in cancer;Kasthuri;J Clin Oncol,2009

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system;Scientific Reports;2024-09-13

2. Accuracy and Completeness of Large Language Models About Antibody–Drug Conjugates and Associated Ocular Adverse Effects;Cornea;2024-08-07

3. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08

4. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

5. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28